Subscribe

54 - Pfizer

A blister pack containing Neurontin anti-epileptic capsules, produced by Pfizer Inc., sits on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Photographer: Chris Ratcliffe/Bloomberg via Getty Images Chris Ratcliffe — Bloomberg via Getty Images

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Read more!

Key Metrics & Financials (Last Fiscal Year)

Revenues ($M)$52824
Revenue Percent Change8.1%
Profits ($M)$7,215.0
Profits Percent Change3.7%
Assets ($M)$171615
Market Value — as of March 31, 2017 ($M)$203,725
Employees96,500
Previous Rank55

Company Facts

Employees96,500
SectorHealth Care
IndustryPharmaceuticals
HQ LocationNew York, NY
CEOIan C. Read
CEO Title-
Websitewww.pfizer.com
Years on Fortune 500 List23

See Full List

Outbrain
Read more!